1. Home
  2. TOVX vs GTBP Comparison

TOVX vs GTBP Comparison

Compare TOVX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.14

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

SELL

Current Price

$3.41

Market Cap

12.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TOVX
GTBP
Founded
2001
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
12.4M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
TOVX
GTBP
Price
$0.14
$3.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.1M
72.7K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 89.07
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.22
52 Week High
$0.49
$236.00

Technical Indicators

Market Signals
Indicator
TOVX
GTBP
Relative Strength Index (RSI) 30.97 26.24
Support Level $0.14 $0.22
Resistance Level $0.25 $7.50
Average True Range (ATR) 0.02 0.39
MACD -0.00 0.09
Stochastic Oscillator 14.48 1.36

Price Performance

Historical Comparison
TOVX
GTBP

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: